- Home
- LPTX vs OPRX Comparison
LPTX vs OPRX Comparison
Compare LPTX & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- OPRX
- Stock Information
- Founded
- LPTX 2011
- OPRX 2006
- Country
- LPTX United States
- OPRX United States
- Employees
- LPTX N/A
- OPRX N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- OPRX Business Services
- Sector
- LPTX Health Care
- OPRX Consumer Discretionary
- Exchange
- LPTX Nasdaq
- OPRX Nasdaq
- Market Cap
- LPTX 119.6M
- OPRX 84.4M
- IPO Year
- LPTX N/A
- OPRX N/A
- Fundamental
- Price
- LPTX $0.39
- OPRX $7.15
- Analyst Decision
- LPTX Buy
- OPRX Buy
- Analyst Count
- LPTX 3
- OPRX 8
- Target Price
- LPTX $8.50
- OPRX $9.06
- AVG Volume (30 Days)
- LPTX 321.2K
- OPRX 1.0M
- Earning Date
- LPTX 05-12-2025
- OPRX 03-12-2025
- Dividend Yield
- LPTX N/A
- OPRX N/A
- EPS Growth
- LPTX N/A
- OPRX N/A
- EPS
- LPTX N/A
- OPRX N/A
- Revenue
- LPTX N/A
- OPRX $92,127,000.00
- Revenue This Year
- LPTX N/A
- OPRX $28.59
- Revenue Next Year
- LPTX N/A
- OPRX $10.52
- P/E Ratio
- LPTX N/A
- OPRX N/A
- Revenue Growth
- LPTX N/A
- OPRX 28.81
- 52 Week Low
- LPTX $0.39
- OPRX $3.78
- 52 Week High
- LPTX $4.79
- OPRX $14.13
- Technical
- Relative Strength Index (RSI)
- LPTX 18.56
- OPRX 67.21
- Support Level
- LPTX $0.40
- OPRX $3.99
- Resistance Level
- LPTX $0.46
- OPRX $5.42
- Average True Range (ATR)
- LPTX 0.03
- OPRX 0.59
- MACD
- LPTX 0.06
- OPRX 0.12
- Stochastic Oscillator
- LPTX 0.00
- OPRX 82.29
Stock Price Comparison Chart: LPTX vs OPRX
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.